Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

FOLFIRI plus aflibercept in the treatment of metastatic colorectal cancer outside of clinical trials

Posted by on Mar 29, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of the combined treatment FOLFIRI with aflibercept (Zaltrap) outside of clinical trials in patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment might be a safe second line option in patients who progressed after first-line...

Read More

Safety of nivolumab and radiation therapy in patients with NSCLC that has spread

Posted by on Mar 19, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated the safety of nivolumab (Opdivo) combined with radiation therapy for patients with advanced non-small cell lung cancer (NSCLC) that has spread. This study found that radiation therapy before or after treatment with nivolumab was not associated with an increased risk of severe side effects. Some background...

Read More

Hypofractionated stereotactic radiotherapy improves outcomes in advanced colorectal cancer

Posted by on Jan 20, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of hypofractionated stereotactic radiotherapy (HSR; high doses of radiation given in fewer sessions than conventional radiotherapy) in advanced colorectal cancer. Researchers suggested that HSR is associated with improved outcomes and manageable side effects. Some background Colorectal cancer is...

Read More

Alectinib vs crizotinib in treating brain or spinal cord tumors in patients with non-small cell lung cancer

Posted by on Jan 12, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating lung cancer that has spread to the brain or spinal cord, crizotinib (Xalkori) or alectinib (Alecensa). The study found that alectinib worked better than crizotinib for treatment of tumors of the brain and spinal cord. Some background Alectinib and crizotinib are two...

Read More

Re-treatment with cetuximab improves cancer outcomes in patients with inoperable colorectal cancer

Posted by on Dec 23, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of cetuximab (Erbitux) in patients with metastatic (spread to other parts of the body) colorectal cancer who did not respond to initial cetuximab treatment. Researchers suggested that this treatment may be beneficial in longer treatment durations. Some background The standard treatment for patients...

Read More

Adding ixabepilone to capecitabine treatment for triple negative breast cancer.

Posted by on Dec 11, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if ixabepilone (Ixempra) and capecitabine (Xeloda) work for treating triple-negative breast cancer in patients with hard to treat disease compared to using capecitabine alone. The study found that adding ixabepilone to treatment resulted in longer survival without the cancer progressing. Some background...

Read More

Adding anthracyclines or carboplatin to standard treatment of breast cancer

Posted by on Nov 17, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...

Read More

Metronomic chemotherapy for HR+ advanced breast cancer

Posted by on Nov 7, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well using metronomic chemotherapy with capecitabine (Xeloda) combined with aromatase inhibitors works for patients with hormone receptor positive advanced breast cancer. The study found that this treatment works well and is safe, and therefore should be considered as a potential treatment option. Some...

Read More